Notícias

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

S&P 500 companies' second-quarter earnings growth reached 70%, driven by the information technology

A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Both have very promising futures.

Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.

Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug's long term commercial potential. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum...

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Just over a month since its initial public offering, SpaceX has delivered one of the weakest post-debut performances of any major U.S. listing since the end of the 2008-2009 financial crisis. A Barron’s analysis found that the stock performed worse than 90% of other U.S. IPOs with market capitalizations of $1 billion or more since July, 2009. Over the first 27 trading days, SpaceX was down 23% from its first day closing price of $161.

JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HDV quietly stacks a 3.1% income stream on top of equity gains that have left the S&P 500 in the dust this year, but the fund's concentrated sector bets carry a catch that most yield-seekers overlook.

If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.

When quality goes on sale, it's time to back up the truck.

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.

In July 2026, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with psychologically impactful moderate to severe glabellar lines, following similar approval in Canada. As the first approved serotype E neurotoxin in Europe with effects beginning as early as eight hours and lasting about two to three weeks, Boey broadens AbbVie’s aesthetics portfolio with a...

It looks like a great buy-and-hold option.

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.

Strong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.

(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.